{"id":"W2143681410","doi":"10.1038/bjc.2011.516","title":"Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer","year":2012,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Terry Fox Foundation; Boehringer Ingelheim","keywords":"Trastuzumab; Lapatinib; Medicine; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Bevacizumab; Adjuvant; Cancer; Cancer research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001209508,0.0005864907,0.003361179,0.0005731843,0.00008242081,0.000242314,0.0005250374,0.0003241468,0.002810367],"category_scores_gemma":[0.00002898986,0.0005320049,0.0008559921,0.0008813633,0.0002880824,0.0004878656,0.00007159828,0.00270016,0.00001817615],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002660702,"about_ca_system_score_gemma":0.008942854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005213878,"about_ca_topic_score_gemma":0.003691971,"domain_scores_codex":[0.9950398,0.0003885569,0.001721262,0.0004308072,0.00144126,0.0009782962],"domain_scores_gemma":[0.997143,0.0002170607,0.001086374,0.0002730313,0.0007575587,0.0005230185],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001085948,0.0004476777,0.0001074126,0.01179467,0.001516135,0.001217197,0.0001770457,0.00001122509,0.000009171196,0.0000410555,0.000663385,0.9839064],"study_design_scores_gemma":[0.002038203,0.0002629003,0.003966557,0.1071154,0.004289042,0.02700927,0.000249762,0.00000425999,0.000004410731,0.00008123003,0.8544194,0.0005595558],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008884898,0.995285,0.000120922,0.0003441204,0.0008618696,0.00111879,0.001036394,0.00001389325,0.001130169],"genre_scores_gemma":[0.001361771,0.9951816,0.0003156793,0.0002681497,0.001837027,0.0002949184,0.00002433318,0.0001957071,0.0005207693],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9833469,"threshold_uncertainty_score":0.9997131,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0989027358661728,"score_gpt":0.4448493664120509,"score_spread":0.3459466305458781,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}